Zobrazeno 1 - 10
of 74
pro vyhledávání: '"James G. Kublin"'
Autor:
Srilatha Edupuganti, Maria G. Pau, Magda Sobieszczyk, Merlin L. Robb, Johannes P. M. Langedijk, M. Juliana McElrath, Lorenz Scheppler, Michal Sarnecki, Susan Buchbinder, Dan H. Barouch, Ian Frank, Kristen W. Cohen, Joseph P. Nkolola, Stephen R. Walsh, Etienne Karita, Hong Van Tieu, Lawrence Corey, Julie A Ake, Guido Ferrari, Steven Nijs, Kenneth H. Mayer, Karen Buleza, Lindsey R. Baden, Katleen Callewaert, Nadine Rouphael, Galit Alter, Georgia D. Tomaras, Paul A. Goepfert, Dimitri Goedhart, Frank Wegmann, Colleen Kelly, James G. Kublin, Lauren Peter, Trevor A Crowell, David C. Montefiori, Frank Tomaka, Philipp Mann, Michael C. Keefer, Daniel J. Stieh, Zelda Euler, Hanneke Schuitemaker
Publikováno v:
The Lancet. HIV
Summary Background Bioinformatically designed mosaic antigens increase the breadth of HIV vaccine-elicited immunity. This study compared the safety, tolerability, and immunogenicity of a newly developed, tetravalent Ad26 vaccine with the previously t
Autor:
Michelle R. Manis, Amanda Hann, Emily Gerth-Guyette, Tobi Akingbade, Vajra Allan, James G. Kublin, Greg Bizilj, Pooja Bansil, Sean C. Murphy, Andrew Bryan, Lynn Robertson, Gwen Ambler, Gonzalo J. Domingo, Maria Kahn, Nickolas A. Styke, Sampa Pal, Mark Layton, Stephanie Zobrist, Richard Ansbro, Jane Myburgh
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 9, p e0257560 (2021)
PLoS ONE, Vol 16, Iss 9, p e0257560 (2021)
Certain clinical indications and treatments such as the use of rasburicase in cancer therapy and 8-aminoquinolines for Plasmodium vivax malaria treatment would benefit from a point-of-care test for glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Autor:
Michele P. Andrasik, Weiping Deng, Yiwen Lu, Bob C. Lin, Ruben O. Donis, Youyi Fong, Mira Baron, Lindsay N. Carpp, Lars W. P. van der Laan, Immune Assays Team, Adrian B. McDermott, Karen Martins, Lindsey R. Baden, Flora Castellino, James G. Kublin, Luis De La Cruz, Honghong Zhou, Chuong Huynh, Rolando Pajon, Amanda Eaton, David Benkeser, Mark Kutner, Dean Follmann, Marcella Sarzotti-Kelsoe, CoVPN Biostatistics Team, Hana M. El Sahly, Charlene McDanal, Jacqueline Miller, Christopher R. Houchens, Nima S. Hejazi, Kathleen M. Neuzil, Spyros A. Kalams, Bhavesh Borate, Coronavirus Efficacy (Cove) Team, David C. Montefiori, Lakshmi Jayashankar, Colleen F. Kelley, Richard A. Koup, Britta Flach, Peter B. Gilbert, Lawrence Corey, Chenchen Yu
Publikováno v:
medRxiv
article-version (status) pre
article-version (number) 4
article-version (status) pre
article-version (number) 4
BackgroundIn the Coronavirus Efficacy (COVE) trial, estimated mRNA-1273 vaccine efficacy against coronavirus disease-19 (COVID-19) was 94%. SARS-CoV-2 antibody measurements were assessed as correlates of COVID-19 risk and as correlates of protection.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ffccfeae7ead57a33edd54278a0c324
https://doi.org/10.1101/2021.08.09.21261290
https://doi.org/10.1101/2021.08.09.21261290
Autor:
Shirley Galbiati, Jessie K. Kennedy, Thomas L. Richie, Stephen L. Hoffman, Natasha Kc, Lisa A. Jackson, Sumana Chakravarty, Eric R. James, Yonas Abebe, B. Kim Lee Sim, James G. Kublin, Sean C. Murphy, Kristen W. Cohen, Gregory A. Deye
Publikováno v:
PLoS Pathogens, Vol 17, Iss 5, p e1009594 (2021)
PLoS Pathogens
PLoS Pathogens
PfSPZ-CVac combines ‘PfSPZ Challenge’, which consists of infectious Plasmodium falciparum sporozoites (PfSPZ), with concurrent antimalarial chemoprophylaxis. In a previously-published PfSPZ-CVac study, three doses of 5.12x104 PfSPZ-CVac given 28
Autor:
James G. Kublin
Publikováno v:
Journal of the International AIDS Society
Autor:
Devan V. Mehrotra, Lindsey R. Baden, Lindsay N. Carpp, Jonathan Fintzi, Ying Huang, Myron S. Cohen, Thomas R. Fleming, David Benkeser, Hana M. El Sahly, Michal Juraska, Ian Hirsch, Peter B. Gilbert, Shu Han, Alex Luedtke, Lawrence Corey, Martha Nason, Kathleen M. Neuzil, Holly Janes, Marco Carone, Michael P. Fay, Youyi Fong, James G. Kublin, Yunda Huang, Erin E. Gabriel, Deborah Donnell, Honghong Zhou, Ollivier Hyrien, An Vandebosch, Iksung Cho, Dean Follmann
Publikováno v:
medRxiv
article-version (status) pre
article-version (number) 1
article-version (status) pre
article-version (number) 1
Background: Several candidate vaccines to prevent COVID-19 disease have entered large-scale phase 3 placebo-controlled randomized clinical trials and some have demonstrated substantial short-term efficacy. Efficacious vaccines should, at some point,
Autor:
Philip Kotze, Fatima Laher, Mary Allen, Peter B. Gilbert, Jia J. Kee, Dishiki Jenny Kalonji, Carter Bentley, Susan W. Barnett, Tricia Philip, Craig Innes, Adrian Puren, Holly Janes, Millicent Atujuna, Nivashnee Naicker, M. Juliana McElrath, Philisiwe B. Makhoba, Gladys Kobane, Girisha Kistnasami, Katlego S. Mapetla, Zakir Gaffoor, Cleon N. Ncayiya, Sanjay Phogat, Vimla Naicker, Simbarashe Takuva, James G. Kublin, Linda-Gail Bekker, Nima S. Hejazi, David Benkeser, Niranjan Kanesa-thasan, Modulakgotla Sebe, Olivier Van Der Meeren, Yunda Huang, Bontle Modibedi, Pamela Mda, Mookho Malahleha, Mpho Sikhosana, Matsontso Mathebula, Pearl Selepe, Amy Ward, Lawrence Corey, Megan Jones, John Hural, Tania Adonis, Sheetal Kassim, Carlos Diaz Granados, Nicole Grunenberg, Shelly Ramirez, Doug Grove, Maphoshane Nchabeleng, Brittany Prigmore, Graeme Meintjes, Erica Lazarus, William Brumskine, Lubbe Wiesner, Nigel Garrett, Marguerite Koutsoukos, Thozama Dubula, Zoe Moodie, Glenda Gray, Nishanta Singh, Michele P. Andrasik
Publikováno v:
The New England journal of medicine. 384(12)
Background A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. A canarypox-protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand. An analogous
Autor:
John R. Mascola, John Hural, Lynn Morris, Erica Lazarus, Catherine Orrell, Hvtn, Juan C Hinojosa, Philip Andrew, Joseph Makhema, Myron S. Cohen, Fatima Laher, Allan C. deCamp, Carter Bentley, Estelle Piwowar-Manning, Lindsey R. Baden, Nyaradzo Mgodi, Julie E. Ledgerwood, Hptn Study Teams, Carolyn Williamson, Lawrence Corey, Nidhi Kochar, Nirupama Sista, Nicole Espy, James G. Kublin, M. Juliana McElrath, David C. Montefiori, Peter B. Gilbert, James I. Mullins, Shelly Karuna, Kyle E. Marshall, Deborah Donnell, Pamela G Mukwekwerere, Magdalena E. Sobieszczyk, David N. Burns, Robinson Cabello, Pedro Gonzales, Hptn, Jorge Sanchez, Glenda Gray, Erika Rudnicki, Srilatha Edupuganti, Yunda Huang, Ian Frank, Michal Juraska, Margarita M. Gomez Lorenzo, April K. Randhawa, Simbarashe Takuva, Javier R. Lama
Publikováno v:
The New England journal of medicine. 384(11)
Background Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. Methods We enrolled at-risk cisgender men and transgender persons in the Americas and Europe in the H
Autor:
Abby Isaacs, Janan Dietrich, Joan Dragavon, Maria P. Lemos, John Hural, Reena K Gulati, M J McElrath, Erica Lazarus, Michele P. Andrasik, Doug Grove, Eva Chung, Robert W. Coombs, Glenda Gray, Adrian Puren, Cecilia Morgan, Fatima Laher, James G. Kublin, Yunda Huang
Publikováno v:
J Acquir Immune Defic Syndr
Background Measurements of HIV exposure could help identify subpopulations at highest risk of acquisition and improve the design of HIV prevention efficacy trials and public health interventions. The HVTN 915 study evaluated the feasibility of self-a
Autor:
Maphoshane Nchabeleng, Fatima Laher, Glenda Gray, Linda-Gail Bekker, Gavin J. Churchyard, Koleka Mlisana, Rephaim Mpofu, Mary Allen, James G. Kublin, Kennedy Otwombe, M. Juliana McElrath
Publikováno v:
PLoS ONE, Vol 16, Iss 1, p e0241708 (2021)
PLoS ONE
PLoS ONE
Benign ethnic neutropenia (BEN) is defined as a neutrophil count of 9 cells/L in healthy individuals and is more common in populations of certain ethnicities, e.g. African or Middle Eastern ethnicity. Neutrophil values are commonly included in eligib